A photo-nano vaccine based on aggregation-induced emission materials
By developing aggregation-induced luminescent materials with D-A-D structure, combining tumor-specific antigens and STING agonists, the light nano vaccine is constructed, and the problem of single modality in photo-immune combined diagnosis and treatment is solved, and multimodal light is achieved The development of diagnostic and treatment agents has the comprehensive performance of near-infrared second-zone emission, photothermal therapy and photodynamic therapy, which significantly improves the effectiveness of tumor treatment.
Patent Information
- Application Number
- CN202311290111.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-28
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-09-28
AI Technical Summary
Existing photonon-nanovaccines lack multimodal performance in combined photo-immune diagnosis and treatment, especially the comprehensive performance of near-infrared second-zone emission, photothermal therapy and photodynamic therapy, making it difficult to achieve high-resolution imaging of deep tissues and excellent photodynamic therapy. Effect.
Using aggregation-induced luminescent material with typical D-A-D structure, nanoparticles with near-infrared two-zone emission, photothermal therapy and photodynamic therapy are prepared by specific synthetic methods, and they are combined with tumor-specific antigens and STING agonist c-d- AMP binds to construct a photonon-vaccine to activate the immune response.
The development of multimodal photodiagnosis and treatment agents has significant near-infrared second-zone emission properties and excellent photothermal treatment effects. It is of great significance to high-resolution imaging and photodynamic treatment of deep tissues, which significantly improves the effect of tumor treatment and Immune activation ability.
Smart Images

Figure CN117343082B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedical nanomaterials, and in particular to a photo-nano vaccine based on aggregation-induced luminescence materials. Background Art
[0002] Nano-vaccines are an emerging field that is currently receiving widespread attention. There are great advantages in using biomimetic nanotechnology to improve tumor vaccines. It can not only nanosize antigens to increase the efficiency of immune activation, but also deliver antigen materials together with immunostimulatory adjuvants to improve the bioavailability of the nano-platform. In addition, nanoparticles can be used as immune adjuvants for cancer vaccines because nanoparticles can be effectively absorbed by antigen-presenting cells (such as dendritic cells) in the body. Recently, photothermal therapy based on nanomaterials has received widespread attention because it can break the physical barriers of solid tumors and improve immunosuppression. It has become one of the most promising tumor treatment methods combined with immunotherapy. At present, nano-photothermal materials are widely used in the field of tumor photoimmunotherapy. Local hyperthermia can cause immune cell death, induce the release of immunoregulatory molecules, and enhance the activation efficiency of dendritic cells.
[0003] Aggregation-induced emission (AIE) molecules have the advantages of high brightness in the aggregated state, large Stokes shift, and strong resistance to photobleaching. At the same time, they can effectively overcome the aggregation quenching (ACQ) phenomenon of traditional fluorophores in the molecular aggregation state, which is of great significance for fluorescence imaging. In addition, AIE molecules have a propeller-shaped conformation in structure, as well as sufficient molecular rotors and (or) oscillators, so that they can freely rotate and (or) vibrate within the molecule in the solution state under light excitation. The strong intramolecular motion causes the energy of the excited state to be consumed mainly through non-radiative decay pathways, thereby promoting the generation of heat and the conversion of photothermal energy into sound waves, which can achieve efficient photothermal therapy and photoacoustic imaging. At the same time, AIE molecules are also an excellent generator of reactive oxygen species (ROS), especially when aggregated, so they can also be used in photodynamic therapy (PDT).
[0004] Currently, there is a lack of a multimodal phototherapy agent that has the performance of near-infrared second-zone emission, photothermal therapy and photodynamic therapy. Therefore, the existing technology needs to be further improved and developed. Summary of the invention
[0005] In view of the above-mentioned deficiencies in the prior art, the object of the present invention is to provide a photo-nano vaccine based on aggregation-induced luminescence materials, aiming to solve the problem of single modality of existing photo-nano vaccines when used for photo-immune combined diagnosis and treatment.
[0006] The technical solution of the present invention is as follows:
[0007] In a first aspect, an aggregation-induced emission material is provided, wherein the structural formula of the aggregation-induced emission material is:
[0008] Wherein X1 and X2 are independently selected from one of S and Se; R1 and R2 are independently selected from H, One of them.
[0009] This structure is a typical DAD structure containing terminal capping groups. The terminal capping can not only increase the solubility of the molecule, but also the twisted structure can increase the fluorescence quantum yield of the molecule, and the stacking is looser, which further enhances the AIE property of the molecule. The structure of the intermediate DAD can make the absorption and emission wavelengths of the molecule red-shifted, with absorption in the near-infrared region 1 and emission in the near-infrared region 2, which has great advantages in the imaging field.
[0010] In a second aspect, a method for preparing an aggregation-induced emission material, wherein the method comprises:
[0011] Dispersing the tin reagent product, 4,7-dibromobenzo[1,2-c:4,5-c']bis([1,2,5]thiadiazole) and tetrakistriphenylphosphine palladium in an organic solvent to obtain a first mixed solution;
[0012] In an inert atmosphere, heating the first mixed solution under reflux overnight to quench the reaction, and obtaining the aggregation-induced emission material through purification;
[0013] The structural formula of the tin reagent product is:
[0014] Wherein, R1 and R2 are independently selected from H, One of them.
[0015] In a third aspect, a method for preparing an aggregation-induced emission material, wherein the method comprises:
[0016] dispersing the tin reagent product, 4,7-dibromo-5,6-dinitrobenzo[c][1,2,5]thiadiazole and tetrakistriphenylphosphine palladium in an organic solvent to obtain a second mixed solution;
[0017] In an inert atmosphere, heating the second mixed solution under reflux overnight to quench the reaction, and obtaining an intermediate product through purification;
[0018] Under the protection of inert gas, the intermediate product is mixed with iron powder and acetic acid to react to obtain a reaction liquid; the reaction liquid is cooled and subjected to extraction treatment to obtain a solid powder;
[0019] The solid powder is mixed with tin dioxide to obtain a mixture, and chloroform and ethanol are added to the mixture in an inert atmosphere for reflux reaction to obtain the aggregation-induced emission material;
[0020] The structural formula of the tin reagent product is:
[0021] Wherein, R1 and R2 are independently selected from H, The inert gas involved may be nitrogen, helium, argon, etc.
[0022] Optionally, in the method for preparing the aggregation-induced emission material, the method for preparing the tin reagent product comprises:
[0023] Add 4,4-dioctyloxy-4-bromo-triphenylamine into a reaction container, add anhydrous tetrahydrofuran into the reaction container under nitrogen protection, and cool to -78°C;
[0024] n-Butyl lithium is added dropwise to the reaction container, and the reaction is carried out for one hour. Tributyltin chloride is added dropwise to the reaction container, and the temperature is raised to room temperature, and the reaction is carried out overnight. The reaction is quenched, and the tin reagent product is obtained through purification.
[0025] Optionally, in the method for preparing the aggregation-induced emission material, the structural formula of the intermediate product is:
[0026]
[0027] Optionally, in the method for preparing the aggregation-induced emission material, the organic solvent comprises: toluene, tetrahydrofuran, dioxane and xylene.
[0028] Optionally, in the method for preparing the aggregation-induced emission material, the molar ratio of the intermediate product to the iron powder is 1:20.
[0029] Optionally, in the method for preparing the aggregation-induced emission material, the molar ratio of the tin reagent product, 4,7-dibromobenzo[1,2-c:4,5-c']bis([1,2,5]thiadiazole) and tetrakistriphenylphosphine palladium is 1:0.4:0.08.
[0030] The method for preparing the aggregation-induced emission material, wherein the molar ratio of the tin reagent product, 4,7-dibromo-5,6-dinitrobenzo[c][1,2,5]thiadiazole and tetrakistriphenylphosphine palladium is 1:0.4:0.08.
[0031] In a fourth aspect, a photo-nano vaccine based on aggregation-induced luminescence material comprises: aggregation-induced luminescence material and tumor-specific antigen; the aggregation-induced luminescence material is the aggregation-induced luminescence material described above.
[0032] Optionally, a photo-nano vaccine is prepared, in which bovine serum albumin is used as a carrier to load AIE molecules to construct phototherapy nanoparticles, and liver cancer-specific antigen GPC3 and AIE molecules are used to construct nanovaccine particles, which are combined with the STING agonist cd-AMP to activate immunity.
[0033] Beneficial effects: Compared with the prior art, the aggregation-induced luminescence material provided by the present invention has molecules with a stronger DA structure, which can make the aggregation-induced luminescence material have significant near-infrared second-zone emission properties. At the same time, the aggregation-induced luminescence material has the performance of near-infrared second-zone emission, photothermal therapy and photodynamic therapy. The aggregation-induced luminescence material is expected to become a potential multimodal photodiagnostic agent. It is of great significance to achieve high-resolution imaging of deep tissues and excellent PDT treatment effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 is the normalized UV absorption curve of TBBTD and TBBSD in tetrahydrofuran solution;
[0035] Figure 2 is the normalized fluorescence emission spectra of TBBTD and TBBSD in tetrahydrofuran solution, λex(TBBTD)=760nm, λex(TBBSD)=816nm;
[0036] Figure 3 is the fluorescence emission spectrum of TBBSD (10 μM) in a mixed solvent of tetrahydrofuran / isopropanol (v / v) with increasing water content, λex=816 nm;
[0037] Figure 4 is the fluorescence intensity of TBBTD and TBBSD (10 μM) in tetrahydrofuran / isopropanol (v / v) mixed solvent with increasing isopropanol content, λex(TBBTD)=760nm, λex(TBBSD)=816nm;
[0038] Figure 5 The particle size distribution and transmission electron microscopy image of TBBSD nanoparticles;
[0039] Figure 6 is the absorption and emission spectra of TBBSD nanoparticles;
[0040] Figure 7 Different concentrations of TBBSD nanoparticles at a power of 1 W cm -2Photothermal curve under 808nm laser irradiation;
[0041] Figure 8 The photothermal curves of TBBSD nanoparticles with a concentration of 20 μM under 808 nm laser irradiation at different powers;
[0042] Fig. 9 is the photothermal stability curve of TBBSD nanoparticles;
[0043] Fig.10 The temperature rise and fall curves and photothermal conversion efficiency calculation of TBBSD nanoparticles;
[0044] Fig.11 As the 808 laser irradiation time increases (1w cm -2 ), fluorescence intensity enhancement factor of TBBSD-NPs and the mixture of TBBSD-NPs (10 μM) and total ROS indicator DCFH;
[0045] Fig.12 Hepa1-6 cells were incubated with different concentrations of TBBSD-NPs and then exposed to dark / white light (808 nm laser, power: 2 W cm -2 ) Cell activity after 5 minutes of irradiation;
[0046] Fig.13 Cell apoptosis test of Hepa1-6 cells after adding different reagents and irradiating for 5 min. The nanoparticle concentration was 50 μg mL -1 ;
[0047] Fig.14 The release of cell immunogenic death-related factors CRT, HMGB1 and HSP70 in Hepa1-6 cells after different treatments. The concentration of TBBSD is 50μg / mL, the concentration of GPC3 is 2μg / mL, and the concentration of AMP is 25μg / mL;
[0048] Fig.15 The results of flow cytometry analysis of CD80 and CD86 expression in dendritic cells after different treatments;
[0049] Fig.16 Results of tumor near-infrared two-zone fluorescence imaging at 0h, 6h, 12h, 24h and 36h after administration of TBBSD-NPs (100μL, TBBSD 5mg / kg body weight);
[0050] Fig.17 The photoacoustic imaging results of the tumors at 0h, 6h, 12h, 24h and 36h after administration to mice;
[0051] Fig.18After the mice were given the drug, 808 nm laser (1.5 W cm -2 ) Thermal imaging of the temperature change of the tumor site within 5 minutes of irradiation;
[0052] Fig.19 The change trend of in situ tumor volume over time after different treatments;
[0053] Fig. 20 The change trend of distal tumor volume over time after different treatments;
[0054] Fig.21 Survival curves of mice treated with different methods;
[0055] Fig. 22 The contents of CD80 and CD86 dendritic cells in lymph nodes after different treatments;
[0056] Fig.23 is the content of CD8+T cells in spleen cells after treatment with different treatment methods;
[0057] Fig.24 is the content of Treg cells in spleen cells after treatment with different treatment methods;
[0058] Fig.25 Immunohistochemical evaluation of lung tissue sections after different treatments for the lung metastasis model;
[0059] Fig.26 Evaluation of memory T cells in the spleen of mice after treatment with no therapeutic modalities. DETAILED DESCRIPTION
[0060] The present invention provides an aggregation-induced luminescence material and a preparation method thereof, as well as a method for constructing a photo-nano vaccine. To make the purpose, technical solution and advantages of the present invention clearer and more specific, the present invention is further described in detail below. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.
[0061] Example 1
[0062] Weigh 4,4-dioctyloxy-4-bromo-triphenylamine (579 mg, 1 mmol) and add it to the sealed tube. Add 10 mL of anhydrous tetrahydrofuran under nitrogen protection and cool to -78 ° C. Then add n-butyl lithium (1.2 mmol) dropwise and react at this temperature for one hour. Then add tributyltin chloride (391 mg, 1.2 mmol) dropwise, warm to room temperature, and react overnight. After the reaction is completed, potassium fluoride solution is used to quench the reaction, dichloromethane is extracted three times, sodium sulfate is dried, and suction is filtered. After removing the solvent, the tin reagent product is obtained, which is directly used in the next step without other purification steps.
[0063] The above obtained tin reagent product was added to a sealed tube, and 4,7-dibromobenzo[1,2-c:4,5-c']bis([1,2,5]thiadiazole) (141 mg, 0.4 mmol) and tetrakistriphenylphosphine palladium (92.4 mg, 0.08 mmol) were weighed, and 5 mL of anhydrous toluene was added as solvent. The reaction was refluxed overnight under nitrogen protection. After the reaction was completed, the reaction was quenched with potassium fluoride solution, extracted with dichloromethane three times, dried with sodium sulfate, and filtered to remove the solvent. The product was purified by chromatography column, and the eluent was petroleum ether / dichloromethane (v / v, 1 / 1) to obtain a blue powder compound TPA-BBTD (122 mg) with a yield of 25%. 1 H NMR(400MHz,THF-d8)δ8.26(d,J=9.0Hz,4H),7.19(d,J=8.9Hz,8H),7.06(d,J=9.0Hz,4H),6.93(d ,J=9.0Hz,8H),4.00(t,J=6.4Hz,8H),1.86–1.79(m,8H),1.60–1.35(m,40H),0.98–0.92(m,12H).
[0064] The synthetic route is as follows:
[0065]
[0066] Example 2
[0067] The tin reagent product was obtained by the synthesis method of Example 1. The tin reagent product (2mmol), 4,7-dibromo-5,6-dinitrobenzo[c][1,2,5]thiadiazole (307mg, 0.8mmol), and tetrakistriphenylphosphine palladium (185mg, 0.16mmol) were added to the sealed tube, followed by 15mL of anhydrous toluene, and reacted overnight under a nitrogen atmosphere. After the reaction was completed, the potassium fluoride solution was quenched, and the dichloromethane was extracted three times, dried with sodium sulfate, filtered, and the solvent was removed by vacuum rotary evaporation. The product was purified by chromatography column, and the eluent was petroleum ether / dichloromethane (v / v, 1 / 1) to obtain a purple powder intermediate 3 (784mg), with a yield of 80%.
[0068] Intermediate 3 (490 mg, 0.4 mmol) and activated iron powder (448 mg, 8 mmol) were added to a three-necked flask, and acetic acid (20 mL) was added after nitrogen was replaced three times. The mixture was then reacted at 80 ° C for 6 hours. After the reaction was completed, the reaction solution was poured into water, extracted with dichloromethane three times, dried with sodium sulfate, filtered, and the solvent was removed by vacuum rotary evaporation to obtain a light yellow solid, which was directly used in the next reaction without further purification.
[0069] The above-obtained light yellow solid and selenium dioxide (222 mg, 2 mmol) were added to a three-necked flask, and nitrogen was replaced three times and chloroform (15 mL) and ethanol (15 mL) were added respectively. After the reflux reaction was completed, it was cooled to room temperature, and the solvent was removed by vacuum rotary evaporation. The product was purified by chromatography column, and the eluent was petroleum ether / dichloromethane (v / v, 1 / 1) to obtain a green powder compound TPA-BBSD (156 mg) with a yield of 30%. The NMR and mass spectrometry characterizations are as follows: 1 H NMR(400MHz,THF-d8)δ8.26(d,J=9.0Hz,4H),7.19(d,J=8.9Hz,8H),7.06(d,J=9.0Hz,4H),6.93(d ,J=9.0Hz,8H),4.00(t,J=6.4Hz,8H),1.86–1.79(m,8H),1.60–1.35(m,40H),0.98–0.92(m,12H).
[0070] The synthetic route is as follows:
[0071]
[0072] Example 3
[0073] N, N-diphenyl-4-(tributylstannyl)-aniline (1064 mg, 2 mmol), 4, 7-dibromo-5, 6-dinitrobenzo[c][1, 2, 5]thiadiazole (307 mg, 0.8 mmol), tetrakistriphenylphosphine palladium (185 mg, 0.16 mmol) were added to the sealed tube, followed by 15 mL of anhydrous toluene, and the mixture was reacted overnight under a nitrogen atmosphere. After the reaction was completed, potassium fluoride solution was used to quench the reaction, and the mixture was extracted with dichloromethane three times, dried with sodium sulfate, filtered, and the solvent was removed by vacuum rotary evaporation. The product was purified by chromatography column, and the eluent was petroleum ether / dichloromethane (v / v, 1 / 1) to obtain purple powder intermediate 4 (433 mg) with a yield of 76%.
[0074] Intermediate 4 (285 mg, 0.4 mmol) and activated iron powder (448 mg, 8 mmol) were added to a three-necked flask. After nitrogen was replaced three times, acetic acid (20 mL) was added, and then the reaction was carried out at 80 ° C for 6 hours. After the reaction was completed, the reaction solution was poured into water, extracted with dichloromethane three times, dried with sodium sulfate, filtered, and the solvent was removed by vacuum rotary evaporation to obtain a light yellow solid, which was directly used in the next reaction without further purification.
[0075] The above-obtained light yellow solid and selenium dioxide (222 mg, 2 mmol) were added to a three-necked flask, and nitrogen was replaced three times and chloroform (15 mL) and ethanol (15 mL) were added respectively. After the reflux reaction was completed, the mixture was cooled to room temperature, and the solvent was removed by rotary evaporation under reduced pressure. The product was purified by chromatography column with petroleum ether / dichloromethane (v / v, 1 / 1) as eluent to obtain a green powder compound TPA-BBSD (79 mg) with a yield of 25%.
[0076] The synthetic route is as follows:
[0077]
[0078] Example 4
[0079] Weigh 4-bromo-N, N-bis(4-(1,2,2-triphenylvinyl)phenyl)aniline (1662 mg, 2 mmol) and add it to a sealed tube. Add 10 mL of anhydrous tetrahydrofuran under nitrogen protection and cool to -78 °C. Then add n-butyl lithium (2.4 mmol) dropwise and react at this temperature for one hour. Then add tributyltin chloride (782 mg, 2,4 mmol) dropwise, warm to room temperature, and react overnight. After the reaction is completed, quench the reaction with potassium fluoride solution, extract three times with dichloromethane, dry with sodium sulfate, filter and remove the solvent to obtain the tin reagent product, which can be directly used in the next reaction without other purification steps.
[0080] The above obtained tin reagent product (2mmol), 4,7-dibromo-5,6-dinitrobenzo[c][1,2,5]thiadiazole (307mg, 0.8mmol), tetrakistriphenylphosphine palladium (185mg, 0.16mmol) were added to the sealed tube, followed by 15mL of anhydrous toluene, and reacted overnight under a nitrogen atmosphere. After the reaction was completed, potassium fluoride solution was used to quench the reaction, dichloromethane was extracted three times, and sodium sulfate was dried. After suction filtration, the solvent was removed by vacuum rotary evaporation, and the product was purified by chromatography column, and the eluent was petroleum ether / dichloromethane (v / v, 1 / 1), and a purple powder intermediate 4 (899mg) was obtained with a yield of 65%.
[0081] Intermediate 6 (692 mg, 0.4 mmol) and activated iron powder (448 mg, 8 mmol) were added to a three-necked flask. After nitrogen was replaced three times, acetic acid (20 mL) was added, and then the reaction was carried out at 80 ° C for 6 hours. After the reaction was completed, the reaction solution was poured into water, extracted with dichloromethane three times, dried with sodium sulfate, filtered, and the solvent was removed by vacuum rotary evaporation to obtain a light yellow solid, which was directly used in the next reaction without further purification.
[0082] The above-obtained light yellow solid and selenium dioxide (222 mg, 2 mmol) were added to a three-necked flask, and nitrogen was replaced three times and chloroform (15 mL) and ethanol (15 mL) were added respectively. After the reflux reaction was completed, the mixture was cooled to room temperature, and the solvent was removed by rotary evaporation under reduced pressure. The product was purified by chromatography column with petroleum ether / dichloromethane (v / v, 1 / 1) as eluent to obtain a green powder compound TPE-TBBSD (118 mg) with a yield of 17%.
[0083] The synthetic route is as follows:
[0084]
[0085] The following experiments were conducted on the aggregation-induced emission materials prepared in the above examples:
[0086] Molecular photophysical properties and photothermal / photodynamic characterization:
[0087] 1. Absorption and emission spectra:
[0088] TBBSD and TBBTD were dissolved in THF to prepare 10 μM, and UV absorption (Shimadzu UV-1600i) and fluorescence emission spectrum tests (Edinburgh fluorescence spectrometer) were performed. Figure 1 As shown, the absorption peaks of TBBSD and TBBTD are 816nm and 760nm, respectively. Figure 2 As shown, the emission spectrum peaks of TBBSD and TBBTD are 1120nm and 1050nm respectively, and both molecules have significant emission properties in the second near-infrared region.
[0089] 2.AIE curve test:
[0090] The emission spectra of TBBSD and TBBTD solutions (10 μM) in THF / isopropanol mixed solvents with isopropanol contents ranging from 0% to 90% were tested. Figure 3 The following are the emission spectra of TBBSD molecules in solvents with different isopropanol contents. Figure 4 The curve showing the change of emission peak intensity at different isopropanol ratios is shown in Figure 2. After the isopropanol content increases to 50%, the fluorescence intensity gradually increases, showing the AIE property.
[0091] 3. Preparation and characterization of nanoparticles and absorption and emission spectra
[0092] Slowly add 500 μL of 1 mg / mL TBBSD THF solution to the 1 mg / mL BSA aqueous solution in a vortex state. After the addition is completed, continue to vortex for 1 min. The prepared product is dialyzed in pure water for 24 hours and then concentrated using an ultrafiltration centrifuge tube to complete the preparation of TBBSD-NPs. Prepare an aqueous solution with a nanoconcentration of 100 μg / mL for dynamic light scattering testing, such as Figure 5 As shown, the particle size of the nanoparticles is about 120nm, and the nanoparticles have good dispersibility ( Figure 6 As shown). Nanoparticles with a TBBSD concentration of 10 μM were prepared and subjected to absorption and emission spectrum tests. The ultraviolet absorption peak of the nanoparticles was at 786 nm, and the emission spectrum peak was at 1060 nm, still showing excellent near-infrared second-zone emission properties.
[0093] 4. Photothermal performance test
[0094] The concentration gradient of TBBSD-NPs was prepared from 0 μM to 30 μM. The dispersion was water with a volume of 100 μL and the power was 1 W cm -2 Under the irradiation of 808nm laser, the real-time temperature detection is carried out using a thermal imager. Figure 7 As shown in the figure, as the concentration of nanoparticles increases, the photothermal effect gradually increases, and at a concentration of 30 μM, the temperature can rise to above 65°C within 5 minutes. Figure 8 As shown in the figure, 10 μM was selected as the test concentration, and the laser power was increased from 0.5 W cm -2 Increased to 1.5W cm -2 , the photothermal effect gradually increases, and at 1.5W cm -2 The temperature can reach 70°C within 5 minutes under 1W cm -2 The light was illuminated for 6 minutes under the power, the temperature was turned off for 6 minutes, and then the light was illuminated again. After 6 cycles, the light and heat stability was studied. Fig. 9 As shown in Figure 2, the nanoparticles still exhibited stable photothermal performance under 6 cycles of illumination. The heating and cooling curves of 10 μM TBBSD-NPs were analyzed and the photothermal conversion efficiency was calculated, as shown in Figure 2. Fig.10 As shown, the photothermal conversion efficiency of TBBSD-NPs was 43.2%.
[0095] 5. Overall ROS performance test
[0096] 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) was used as a ROS indicator to detect 808 nm laser (1 W cm -2) irradiation. First, add the ethanol solution of DCFH-DA (1mM, 0.5mL) to 2mL NaOH solution (0.01M) and stir at room temperature for 30 minutes to hydrolyze DCFH-DA into DCFH. Then, neutralize the hydrolyzate with 10mL 1×PBS with pH 7.4 to obtain an activated ROS indicator (40μM, 12.5mL), store at 4°C in the dark for later use. Then, mix the activated ROS indicator (40μM) and the AIE molecule in PBS, so that the final concentrations of the ROS indicator and the AIE molecule are 10μM, respectively. After irradiation with 808 laser for different times, a fluorescence spectrometer (EdinburghFS5) is used to detect the fluorescence intensity of 2',7'-dichlorofluorescein triggered by the ROS generated by the AIE molecule to reflect the ROS generation. The excitation wavelength is 488nm, and the fluorescence signal in the range of 490-600nm is collected. As Fig.11 As shown, DCFH and nanoparticles alone had almost no fluorescence. After the addition of TBBSD-NPs and TBBSD-NPs, the DCFH fluorescence gradually increased with the extension of irradiation time, proving that both TBBSD-NPs and TBBSD-NPs can effectively produce ROS under 808 laser irradiation.
[0097] Animal and cell experiments:
[0098] 1. In vitro cytotoxicity assay
[0099] The cytotoxicity of TBBSD-NPs was evaluated by measuring the viability of hepatoma cells (Hepa1-6 cell line) under light / dark conditions. Briefly, an appropriate amount of Hepa1-6 cells in logarithmic growth phase were cultured in 96-well plates (approximately 5,000 cells / well) and cultured for 12 h. Subsequently, the cell culture medium was replaced with new TBBSD-NPs containing different TBBSD concentrations (0.2, 0.5, 1, 2, 5, 10, 25, 50, and 100 μg mL -1 ) medium, and the cells were cultured for another 12 hours. After incubation, the phototoxic group was irradiated with an 808 nm laser for 5 minutes per well (power: 2 W cm -2 ), CCK-8 reagent (Dojindo Molecular Technologies, Japan) was used to detect surviving cells, and cell viability was calculated based on absorbance. In the dark toxicity group, CCK-8 reagent was used to detect cell viability directly after incubation. Fig.12 As shown, in the range of 0-100 μg mL -1 Within the concentration range, under no light conditions, the activity of cells was basically not affected. In the light group, the cell activity dropped sharply, showing strong phototoxicity.
[0100] Cell apoptosis experiment: An appropriate amount of Hepa1-6 cells in the logarithmic growth phase were inoculated in a 6-well plate (about 50,000 cells / well) and cultured for 12 hours. Then TBBSD-NPs were added to the wells. The concentration of TBBSD was 50 μg mL -1 After 12 hours, the 808 nm laser (2 W cm -2 ) irradiate the cells for 5 minutes. Digest and collect the cells with trypsin without EDTA. Stain the cells with Annexin V-FITC / PI apoptosis detection kit and detect them by flow cytometry. Fig.13 As shown, the apoptosis of cells in the experimental group with nanoparticles and light increased sharply, while the cell activity in other control groups was basically unaffected.
[0101] 2. In vitro ICD experiment
[0102] An appropriate amount of Hepa 1-6 cells in the logarithmic growth phase were cultured in a glass-bottomed culture dish for 24 hours (about 50,000 cells / well) and then divided into four groups: 1) PBS; 2) PBS+L; 3) TBBSD-NPs; 4) TBBSD-NPs+L; the concentration of TBBSD in groups 3 and 4 was 50 μg / mL. After washing twice with culture medium, the cells in groups 2 and 4 were exposed to 808 nm laser irradiation (2 W cm -2 ) for 5 minutes, and then incubated at 37°C for another 30 minutes. Each group of cells was fixed and labeled and stained with anti-CRT, anti-HMGB1 and anti-HSP70 antibodies, and then imaged using confocal laser scanning (CLSM) (Olympus FV3000). Conditions: Excitation wavelength: DAPI is 405nm, green fluorescent secondary antibody is 488nm, red fluorescent secondary antibody is 561nm; emission: DAPI 430-470nm, green fluorescent secondary antibody is 500-540nm, red fluorescent secondary antibody is 550-650nm. Fig.14 As shown, the expression levels of cellular immunogenicity-related factors CRT, HMGB1 and HSP70 in the experimental group with nanoparticles plus light were significantly different from those in other control groups, indicating that photothermal therapy triggered immunogenic cell death.
[0103] 3. In vitro DC activation
[0104] Mouse bone marrow-derived dendritic cells (BM-DCs) were derived from B6 mice. Immature BM-DCs (4×10 6) were cultured in RPMI-1640 (GIBCO) supplemented with FBS (10%, GIBCO), 2-mercaptoethanol (2-ME, 0.8 ng / mL, Sigma Aldrich) and mouse granulocyte-macrophage colony stimulating factor (GM-CSF, 20 ng / mL, PeproTech) for 72 hours. 5 Cells / well were placed in 6-well plates) and treated as follows: 1) PBS group; 2) NPs group; 3) NPs+GPC3 group; 4) NPs+GPC3+AMP group; 5) NPs+GPC3+AMP+L supernatant group. The concentration of TBBSD was 50 μg mL -1 , GPC3 concentration was 2 μg mL -1 , AMP concentration was 25 μg mL -1 , L supernatant ratio 1:100 (v / v). L supernatant comes from the supernatant of Hepa1-6 cells after laser irradiation (10,000 cells / mL culture medium, 808 nm laser, power 2 W cm -2 , irradiated for 5 min). After 24 h of co-incubation, the cells were collected. The cells were labeled with the following antibodies: anti-CD11c-FITC, anti-CD80-PE, anti-CD86-APC (eBioscience). Flow cytometry was used to detect the differentiation and maturation of BM-DCs in each group. BD flow cytometer was used for flow cytometry, and the flow analysis results were analyzed using Flow-jo software (Tree Star, Inc.). Fig.15 As shown, the results of flow cytometry analysis showed that the expression of CD86 and CD80 in DC cells treated with the cell supernatant of the nanoparticles + GPC3 antigen + AMP adjuvant + light group was significantly increased, indicating that the cell supernatant of photothermal therapy can activate DC cells in vitro.
[0105] 3. In vivo two-zone fluorescence, photoacoustic and photothermal imaging
[0106] Male C57BL / 6J mice (14 ± 2 g, 5-6 weeks old) were purchased from Guangzhou Jicui Pharmaceutical Animal Research Center and were selected to establish the xenograft Hepa1-6 tumor model. The mice were provided with fresh food and water free of charge every day and were adaptively housed for at least 7 days before the experiment. Hepa1-6 cells (5 × 10 6 ) was injected subcutaneously into the right hind hip of the mouse. After about 7 to 10 days, the tumor was fully established.
[0107] TBBSD-NPs (100 μL, TBBSD 5 mg / kg body weight) were injected into Hepa1-6 xenograft tumor mice via the tail vein. Then, the mice were subjected to two-zone fluorescence imaging and photoacoustic imaging at different time points (0, 6, 12, 24 and 36 hours) after the injection of NPs. The two-zone fluorescence was acquired using a commercial Series II 900 / 1700 imaging system, and the photoacoustic imaging was acquired using a LOIS-3D photoacoustic imager (Tomowave). The two-zone fluorescence imaging used 808 nm excitation and a 1000 nm filter. Photoacoustic imaging used 808 nm excitation and a frequency of 21 MHz. Fig.16 As shown in the mouse fluorescence second zone imaging, it can be seen that obvious signals appeared 6 hours after administration, and the signal at the tumor site reached the highest level 24 hours after administration. Fig.17 As shown, photoacoustic signals appeared in the mouse tumor site 6 hours after administration and reached the highest value 24 hours after administration, which was consistent with the trend of the fluorescence signal in the second zone, indicating that TBBSD-NPs can effectively realize fluorescence and photoacoustic imaging of the mouse tumor site.
[0108] In terms of in vivo photothermal imaging, 24 h after intravenous injection of TBBSD-NPs (100 μL, TBBSD 5 mg / kg body weight), the tumor site was monitored using a FLIR E60 camera under the influence of 808 nm laser (1.5 W cm -2 ) Temperature change after 5 min of irradiation. Under the same laser irradiation conditions, mice tumors injected with saline (100 μL) were used as controls. Fig.18 As shown, 24 hours after the administration of the mice, the temperature of the tumor site in the nanoparticle group gradually increased with the illumination time within 5 minutes, while the temperature in the normal saline group increased very little with the increase of illumination time, indicating that TBBSD-NPs can produce obvious photothermal therapy effects in living animals under the irradiation of 808nm laser.
[0109] 4. The therapeutic effect of photo-nano vaccine on liver cancer in mice
[0110] When the tumor size reached ~100mm3, the mice were randomly divided into 5 groups and treated with different treatments (n=6 / group): 1) normal saline; 2) NPs+GPC3; 3) NPs+GPC3+AMP; 4) NPs+GPC3+L; 5) NPs+GPC3+AMP+L. Among them, TBBSD5mg / kg body weight, GPC3 0.5mg / kg body weight, AMP 2.4mg / kg body weight. NPs were administered by tail vein injection, and GPC3 and AMP were administered by subcutaneous injection. NPs were administered once on day 0, and GPC3 and AMP were administered three times on days 4, 9, and 14. Groups 4 and 5 received photothermal therapy on day 1 (1.5W cm-2 , 808nm near-infrared irradiation for 5min). On the 15th day, the distal tumor (5×10 6 The tumor size of each group was measured and recorded, and the survival rate of each group of mice was calculated. The relative volume of the tumor was calculated as V = ab 2 / 2, where a and b represent the maximum and minimum diameters respectively. Fig.19 As shown in the figure, the volume of the in situ tumors in mice treated with NPs+GPC3+AMP+light was basically eliminated, and there was no sign of recurrence over time, while the tumor volumes of mice in other control groups gradually increased after treatment, showing a trend of recurrence. Fig. 20 As shown in the figure, the growth of subcutaneous distal tumors in mice treated with NPs+GPC3+AMP+light was effectively inhibited, while the subcutaneous distal tumors of mice in other control groups showed different degrees of growth trends. This shows that mice treated with light therapy and vaccines can not only achieve effective treatment of in situ tumors, but also form immune memory and effectively kill newly implanted distal tumors. Fig.21 As shown, the effective survival rate of mice treated with NPs+GPC3+AMP+light reached 100% within 50 days, which was significantly higher than that of other control groups.
[0111] 5. In vivo immune index detection
[0112] The mice in the above groups were sacrificed on the 21st day. The mice were immediately immersed in a 75% alcohol solution for 3 minutes, and the lymph nodes and spleen were surgically removed and collected. For the lymph nodes, they were digested with cathepsin at 37°C for 10 minutes, and the digestion was terminated by adding culture medium containing FBS. After washing the cells twice with PBS, DC cells were stained with anti-CD11c-FITC, anti-CD80-PE and anti-CD86-APC (eBioscience). CD11c+CD80+CD86+ cells are defined as mature dendritic cells. Fig. 22 As shown, the number of mature dendritic cells in the lymph nodes of mice treated with NPs+GPC3+AMP+light was significantly higher than that of other control groups, indicating that the mice treated with light and vaccine can effectively activate their own immune system.
[0113] For the spleen, chop it into small pieces with scissors. Pass it through a 70-micron cell strainer with 2 mL of PBS buffer and collect it in a 50-mL centrifuge tube. Add an additional 3 mL of RBC lysis buffer to the centrifuge tube and place it at room temperature for 20 minutes to lyse the RBCs. Add 5 mL of culture medium containing FBS to stop the reaction. Then wash the cells twice with PBS. Splenic lymphocytes are then labeled as follows: anti-CD3-APC, anti-CD4-FITC, and anti-CD8a-PE / anti-Foxp3-PE antibodies (Thermo Fisher Scientific). Use a BD flow cytometer for detection and use Flow-jo software to analyze the test results. Fig.23 As shown, the CD8+T cells in the spleen of mice treated with NPs+GPC3+AMP+light increased significantly, indicating that T cells can be activated by photothermal and vaccine treatment. Fig.24 As shown, the immunosuppressive Treg cells in mice treated with NPs+GPC3+AMP+light were significantly reduced, further illustrating the activation of the immune system and proving the effectiveness of photothermal tumor vaccines.
[0114] 6. Treatment of lung metastasis
[0115] Male C57BL / 6J mice (14±2g, 5-6 weeks old) were purchased from Guangzhou Jicui Pharmaceutical Animal Research Center. The mice were provided with fresh food and water free of charge every day and were adaptively fed for at least 7 days before the experiment. Hepa1-6 cells (5×10 6 ) was injected subcutaneously into the right hind hip of the mouse. After about 7 to 10 days, the subcutaneous tumor was fully established. When the tumor size reached ~100mm 3 At the same time, the mice were randomly divided into 5 groups and treated with different treatments (n=6 / group): 1) normal saline; 2) NPs+GPC3; 3) NPs+GPC3+AMP; 4) NPs+GPC3+L; 5) NPs+GPC3+AMP+L. Among them, TBBSD was 5 mg / kg body weight, GPC3 was 0.5 mg / kg body weight, and AMP was 2.4 mg / kg body weight. NPs were administered by tail vein injection, and GPC3 and AMP were administered by subcutaneous injection. NPs were administered once on day 0, and GPC3 and AMP were administered three times on days 4, 9, and 14. Groups 4 and 5 received photothermal therapy on day 1 (1 W cm -2, 808nm near-infrared irradiation for 5min). On the 15th day, Hepa1-6 cells (5×106 cells / mouse) were injected through the tail vein. The mice in the above groups were sacrificed on the 21st day. The mice were immediately immersed in 75% alcohol solution for 3 minutes, and the spleen was surgically removed and collected, and chopped into small pieces with scissors. Pass 2mL PBS buffer through a 70-micron cell filter and collect it in a 50-ml centrifuge tube. Add an additional 3mL of RBC lysis buffer to the centrifuge tube and place it at room temperature for 20 minutes to lyse RBCs. Add 5mL of culture medium containing FBS to stop the reaction. Then wash the cells twice with PBS. Splenic lymphocytes were then labeled as follows: anti-CD3-APC, anti-CD44-FITC and anti-CD62L-PE antibodies (Thermo Fisher Scientific, USA) were used for staining. Tcm: memory T cells CD3+CD44+CD62+. As Fig.25 As shown in the figure, in different treatment groups, the lung tissue sections of mice treated with NPs+GPC3+AMP+light were normal, with no lung metastases, while other control groups all had lung metastases, indicating that the photothermal tumor vaccine can effectively inhibit tumor metastasis. Further evaluation of the immune memory effect of the vaccine showed that the spleen memory T cells of mice treated with NPs+GPC3+AMP+light increased significantly, indicating that mice treated with the photothermal tumor vaccine can form immune memory and effectively inhibit the recurrence and metastasis of tumors.
[0116] 7. Ethical Approval and Consent to Participate
[0117] This study complied with the ethical guidelines of the Declaration of Helsinki, revised in 2013. Experiments using mice were approved by the Ethics Committee (Jinan University), and experiments on animals were performed according to standard guidelines approved by the Animal Welfare Committee (Jinan University, China).
[0118] 8. Statistical Analysis
[0119] Unless otherwise stated, all data are presented as mean ± SD. Statistical differences between treatment and control groups were analyzed by one-way or two-way ANOVA and Tukey post hoc test (multiple comparisons) using GraphPad Prism version 8.0 software. Survival data were analyzed using the log-rank test. * indicates statistically significant differences, p < 0.05; **, p < 0.01; and ***, p < 0.001.
[0120] It should be understood that the application of the present invention is not limited to the above examples. For ordinary technicians in this field, improvements or changes can be made based on the above description. All these improvements and changes should fall within the scope of protection of the claims attached to the present invention.
Claims
1. A photo-nano vaccine based on aggregation-induced luminescence material, characterized in that: It comprises: an aggregation-induced luminescent material and a tumor-specific antigen; the structural formula of the aggregation-induced luminescent material is: , wherein X1 and X2 are independently selected from one of S and Se; R1 and R2 are ; The photo-nano vaccine is a phototherapy nanoparticle constructed by using bovine serum albumin as a carrier to load aggregation-induced luminescence material molecules, and the liver cancer-specific antigen GPC3 is combined with the phototherapy nanoparticles to construct the photo-nano vaccine, which is combined with the STING agonist cd-AMP to activate immunity.
2. The photo-nano vaccine according to claim 1, characterized in that: The preparation method of the aggregation-induced emission material comprises: Dispersing the tin reagent product, 4,7-dibromobenzo[1,2-c:4,5-c']bis([1,2,5]thiadiazole) and tetrakistriphenylphosphine palladium in an organic solvent to obtain a first mixed solution; In an inert atmosphere, heating the first mixed solution under reflux overnight to quench the reaction, and obtaining the aggregation-induced emission material through purification; The structural formula of the tin reagent product is: , where R1 and R2 are .
3. The photo-nano vaccine according to claim 1, characterized in that The preparation method of the aggregation-induced emission material comprises: dispersing the tin reagent product, 4,7-dibromo-5,6-dinitrobenzo[c][1,2,5]thiadiazole and tetrakistriphenylphosphine palladium in an organic solvent to obtain a second mixed solution; In an inert atmosphere, heating the second mixed solution under reflux at 110-115° C. overnight to quench the reaction, and obtaining an intermediate product through purification; Under the protection of inert gas, the intermediate product is mixed with iron powder and acetic acid to react to obtain a reaction liquid; the reaction liquid is cooled and subjected to extraction treatment to obtain a solid powder; The solid powder is mixed with tin dioxide to obtain a mixture, and chloroform and ethanol are added to the mixture in an inert atmosphere to reflux at 70-75° C. to obtain the aggregation-induced emission material; The structural formula of the tin reagent product is: , where R1 and R2 are .
4. The photo-nano vaccine according to claim 2 or 3, characterized in that: The preparation method of the tin reagent product comprises: Add 4,4-dioctyloxy-4-bromo-triphenylamine into a reaction vessel, add anhydrous tetrahydrofuran into the reaction vessel under nitrogen protection, and cool to -78- -80°C; n-Butyl lithium is added dropwise to the reaction container, and the reaction is carried out for 60-70 minutes. Tributyltin chloride is added dropwise to the reaction container, and the temperature is raised to room temperature, and the reaction is carried out overnight. The reaction is quenched, and the tin reagent product is obtained through purification.
5. The photo-nano vaccine according to claim 3, characterized in that: The structural formula of the intermediate product is: 。 6. The photo-nano vaccine according to claim 2 or 3, characterized in that: The organic solvent includes: toluene, tetrahydrofuran, dioxane and xylene.
7. The photo-nano vaccine according to claim 3, characterized in that: The molar ratio of the intermediate product to the iron powder is 1:
20.
8. The photonano vaccine according to claim 2, characterized in that The molar ratio of the tin reagent product, 4,7-dibromobenzo[1,2-c:4,5-c']bis([1,2,5]thiadiazole) and tetrakistriphenylphosphine palladium is 1:0.4:0.
08.
9. The photo-nano vaccine according to claim 3, characterized in that: The molar ratio of the tin reagent product, 4,7-dibromo-5,6-dinitrobenzo[c][1,2,5]thiadiazole and tetrakistriphenylphosphine palladium is 1:0.4:0.08.
